• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Action Mechanism of probiotics effective in preventing the onset of intractable dementia and brain-gut correlation.

Research Project

Project/Area Number 20K06425
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 42020:Veterinary medical science-related
Research InstitutionObihiro University of Agriculture and Veterinary Medicine

Principal Investigator

Ishii Toshiaki  帯広畜産大学, 畜産学部, 教授 (50264809)

Project Period (FY) 2020-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2022: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2021: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
KeywordsB. breve A1 [MCC1274] / MPTP / パーキンソン病 / 難治生認知障害 / 記憶消去 / 脳-腸-微生物相関 / 海馬 / neuropsin / 難治性認知症 / ビフィズス菌 / プロバイオティクス / 脳腸相関
Outline of Research at the Start

パーキンソン病(PD)は運動症状以外にも難治性の認知障害を併発するがその有効な治療薬は存在しない。研究代表者はPDモデルマウス(PDマウス)の記憶能力を詳細に調べた結果、認知障害発症機構の解明に成功した。本研究は、PDの認知症の発症を予防するプロバイオティクスの検索過程でその有効性を認めたビフィズス菌特定株の作用機構を解明することで、これまで曖昧であった腸のマイクロバイオームと脳の両者間に存在する腸脳軸(腸脳相関)の本体を明らかにすると同時に、PDの難治性認知障害に対して安全性の高い治療あるいは予防に向けたプロバイオティクス有効活用による機能性食品開発の手がかりを見出す。

Outline of Final Research Achievements

We generated a mouse model of Parkinson's disease (PD mice) by intraperitoneal injection of MPTP, which destroys DA neurons in the substantia nigra of the midbrain, and B. breve A1 restored the abnormal hyper- extinction of hippocampal memory exhibited by PD mice to normal levels. B. breve A1 restored neuropsin mRNA and protein expression in the hippocampus of PD mice, resulting in normalizing synaptic protein expression and spine density on dendrites in the CA1 region and in possibly normalizing attenuation of inhibitory GABAergic neurotransmission. Our findings also suggest that the cranial normalizing neural mechanism of B. breve A1 is partially mediated by the activation of integrin-linked kinase and its downstream Akt in hippocampal neurons.

Academic Significance and Societal Importance of the Research Achievements

PDの認知症の発症を予防するプロバイオティクスの検索過程でその有効性を認めたBifidobacterium breve strain A1 [MCC1274] (B. breve A1)の作用機構を解明し、PDの難治性認知障害に対して安全性の高い治療あるいは予防に向けたプロバイオティクス有効活用による機能性食品開発の手がかりを見出すことが出来た。また、B. breve A1はGABA-A受容体拮抗薬による不随意運動の亢進を回復させたことから(特願2022-089546 抗てんかん用組成物 [発明者:石井利明])、B. breve A1はてんかん発作の予防にも有効である可能性が示唆された。

Report

(4 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (3 results)

All 2022 2021 Other

All Journal Article (1 results) (of which Peer Reviewed: 1 results,  Open Access: 1 results) Remarks (1 results) Patent(Industrial Property Rights) (1 results)

  • [Journal Article] Oral Administration of Probiotic Bifidobacterium breve Improves Facilitation of Hippocampal Memory Extinction via Restoration of Aberrant Higher Induction of Neuropsin in an MPTP-Induced Mouse Model of Parkinson’s Disease2021

    • Author(s)
      Ishii Toshiaki、Furuoka Hidefumi、Kaya Motohiro、Kuhara Tetsuya
    • Journal Title

      Biomedicines

      Volume: 9 Issue: 2 Pages: 167-167

    • DOI

      10.3390/biomedicines9020167

    • Related Report
      2021 Research-status Report 2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Remarks] 石井利明のホームページ

    • URL

      http://www.obihiro.ac.jp/~yakuri141/

    • Related Report
      2022 Annual Research Report 2021 Research-status Report 2020 Research-status Report
  • [Patent(Industrial Property Rights)] 抗てんかん用組成物2022

    • Inventor(s)
      石井利明
    • Industrial Property Rights Holder
      石井利明
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2022-089546
    • Filing Date
      2022
    • Related Report
      2022 Annual Research Report

URL: 

Published: 2020-04-28   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi